The Follicular Lymphoma International Prognostic Index (FLIPI) is a useful tool for the prognostic assessment of follicular lymphoma but beta-2 microglobulin (B2M) was not incorporated in this index. We aimed to compare the predictive value of B2M, FLIPI and other prognostic factors not included in the FLIPI index for overall survival (OS), complete remission (CR), and time to treatment failure (TTF) in a nonselected follicular lymphoma series.
Methods and study design
Retrospective univariate and multivariate analysis of the prognostic value (for OS, CR, TTF) of B2M, FLIPI and other prognostic variables in follicular lymphoma was conducted in a cohort of follicular lymphoma patients between 1987 and 2007.
Results
One hundred and six patients were studied. In univariate analysis B2M and B symptoms were significantly associated with OS, and FLIPI only detected two risk levels. In multivariate analysis of OS only two significant variables were found: FLIPI and B2M. Multivariate analysis of CR showed that normal B2M, absence of a bulky mass, uninvolved bone marrow, and chemotherapy with rituximab were significant predictors of CR. FLIPI (three levels), B2M, bone marrow infiltration, and chemotherapy with rituximab were significantly associated with TTF.
Conclusions
We found a high predictive value of B2M for OS, CR, and TTF. B2M and FLIPI were the most important variables to predict OS. However, in our series FLIPI differentiated only between two mortality risk levels.
HorningS.J.: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol, 20: 75–80, 1993.
2.
CzuczmanM.S., WeaverR., AlkuzwenyB., BerlfeinJ., Grillo-LópezA.J.: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol, 22: 4711–4716, 2004.
3.
FisherR.I., LeBlancM., PressO.W., MaloneyD.G., UngerJ.M., MillerT.P.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol, 23: 8447–8452, 2005.
4.
SchmitzN., BuskeC., GisselbrechtC.: Autologous stem cell transplantation in lymphoma. Sem Hematol, 44: 234–345, 2007.
PlancarteF., López-GuillermoA., ArenillasL., MontotoS., GinéE., MuntañolaA., FerrerA., VillamorN., BoschF., ColomoL., BalaguerO., CampoE., MonserratE.: Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol, 76: 58–63, 2006.
8.
RodriguezJ., CabanillasF., McLaughlinP., SwanF., RodriguezM., HagemeisterF., RomagueraJ.: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the “tumor score”. Ann Oncol, 3: 711–717, 1992.
9.
ChesonB.D., HorningS.J., CoiffierB., ShippM.A., FisherR.I., ConnorsJ.M.: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Study Group. J Clin Oncol, 17: 1244–1253, 1999.
10.
CoxD.R.: Regression model and life tables. J Am Stat Assoc, 34: 187–220, 1972.
11.
KaplanE.L., MeierP.: Non parametric estimation from incomplete observation. J Am Stat Assoc, 53: 457–481, 1958.
12.
CabanillasF., RodriguezM.A., SwanF.Jr.: Recent trends in the management of lymphoma at M.D. Anderson Cancer Center. Sem Oncol, 17(6 Suppl 10): 28–32, 1990.
13.
HiddemannW., KnebaM., DreylingM., SchmitzN., LengfelderE., SchmitsR., ReiserM., MetznerB., HarderH., Hegewisch-BeckerS., FischerT., KropffM., ReisH.E., FreundM., WörmannB., FuchsR., PlankerM., SchimkeJ., EimermacherH., TrümperL., AldaoudA., ParwareschR., UnterhaltM.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106: 3725–3732, 2005.
14.
HeroldM., HaasA., SrockS., NeserS., Al-AliK.H., NeubauerA., DölkenG., NaumanR., KnaufW., FreundM., RohbergR., HöffkenK., FrankeA., IttelT., KettnerE., HaakU., MeyU., KlinkensteinC., AssmannM., von Grünhagen: Rituximab added to first line mitoxantrone, chlorambucil, and prednisone followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol, 25: 1986–1992, 2007.
15.
SallesG., MounierN., de GuibertS., MorschhauserF., DoyenC., RossiJ.F., HaiounC., BriceC., MahéB., BouabdallahR., AudhuyB., FermeC., DartigeasC., FeugierP., SebbanC., XerriL., FoussardC.: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: result of the GELA-GOELAMS FL2000 study. Blood, 112: 4824–4831, 2008.
16.
CzuczmanM.S., Grillo-LópezA.J., AlkuzwenyB., WeaverR., LaroccaA.: Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma, 47: 1830–1840, 2006.
17.
BuskeC., HosterE., DreylingM., HasfordJ., UnterhaltM., HiddemannW.: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low - risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with respect to treatment outcome. Blood, 108: 1504–1508, 2006.
18.
San MiguelJ., DurieB.G., CrowleyJ.J., BarlogieB., BladéJ., BoccadoroM., ChildJ.A., Avet-LoiseauH., KyleR.A., LahuertaJ.J., LudwigH., MorganG., PowlesR., ShimizuK., ShustikC., SonneveldP., TosiP., TuressonI., WestinJ.: International Staging System for multiple myeloma. J Clin Oncol, 23: 3412–3420, 2005.
19.
JohnsonP.W., WhelanJ., LonghurstS., StepniewskaK., MatthewsJ., AmessJ., NortonA., RohatinerA.Z., ListerT.A.: Beta-2 microglobulin: a prognostic factor in diffuse aggressive non Hodgkin's lymphomas. Br J Cancer, 67: 792–797, 1993.
20.
DimopoulosM.A., CabanillasF., LeeJ.J., SwanF., FullerL., AllenP.K., HagemeisterF.B.: Prognostic role of serum beta-2 microglobulin in Hodgkin's disease. J Clin Oncol, 11: 1108–1111, 1993.
21.
FedericoM., GuglielmiC., LuminariS., MammiC., MarcheselliL., GianelliU., MaioranaA., MerliF., BelleiM., PozziS., StelitanoC., LazzaroA., GobbiP.G., BaldiniL., BergantiniS., FregoniV., BrugiatelliM.: Prognostic relevance of serum beta-2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens: A GISL study. Haematologica, 92: 1482–1488, 2007.
